Hidradenitis Suppurativa News

MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.

As the year comes to a close, Healio Dermatology has assembled this year’s top hidradenitis suppurativa articles.

An in-depth interview about the effects of the CMS’s 2025 physician fee schedule on patient access topped Healio Dermatology’s most-read articles of November, with FDA news also garnering attention.

Hidradenitis suppurativa was linked to adverse maternal and offspring outcomes during the peripartum period and in the long-term, according to a study.

The FDA has approved Bimzelx for the treatment of moderate to severe hidradenitis suppurativa in adults, UCB announced in a press release.

Genetic variants found in hidradenitis suppurativa may be correlated to genetic variants in coronary artery disease and diabetes, according to a study.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.

Researchers have dosed the first patient in a phase 2 trial evaluating AVTX-009 for the treatment of hidradenitis suppurativa, Avalo Therapeutics announced in a press release.

The FDA’s inaction approving sunscreen ingredients as well as studies about endocrine-disrupting chemicals in personal care products and Ozempic’s impact on hidradenitis suppurativa led Healio Dermatology’s most-read articles in September.